Atara Biotherapeutics Inc
NASDAQ:ATRA
| Market Cap (Intraday) | 82.50M |
| Current PE | 14.24 |
| Forward PE | 5.17 |
| 2yr Forward PE | 133.89 |
| 10-Day MA | $12.08 |
| 50-Day MA | $10.53 |
| 200-Day MA | $9.32 |
Atara Biotherapeutics Inc Stock, NASDAQ:ATRA
1280 Rancho Conejo Boulevard, Suite 200, Thousand Oaks, California 91320
United States of America
Phone: +1.805.623.4211
Number of Employees: 153
Description
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.